Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 2 of 8412345...102030...Last »

Trulicity Combo Shows Improved Blood Sugar Control

Eli Lilly published results from a new Phase IIIb study of Trulicity (dulaglutide) in combination with a SGLT-2 inhibitor showing improved blood sugar control in adults with type 2 diabetes.

Read More »

Soccer is basically medicine, some researchers argue

Compared to inactive people, recreational soccer players have lower cholesterol, blood pressure and resting heart rates as well as less fat mass, a research review suggests.

Read More »

Novo’s diabetes pill impresses in first big study

The world’s largest diabetes drugmaker, Novo Nordisk, presented the first successful data from a large final-stage study of a pill the company hopes will transform the diabetes market.

Read More »

AbbVie’s Elagolix Hits Primary Endpoints for Uterine Fibroids

AbbVie and Neurocrine Biosciences’ Phase III ELARIS UF-1 clinical trial of elagolix for uterine fibroids hit its primary endpoint.

Read More »

Genes may not predict low-fat or low-carb diet success

People who try to avoid junk food may lose similar amounts of weight on a low-carb or low-fat diet even when their genetics suggest that one of these options should be better for them.

Read More »

Aimmune’s peanut allergy drug meets main goal

U.S. drug developer Aimmune Therapeutics Inc.’s peanut allergy drug met the main goal of an eagerly awaited late-stage study.

Read More »

Eli Lilly and Hanmi Shutter a Failed Phase II RA Trial

Eli Lilly and its Korean collaborative partner Hanmi Pharmaceutical stopped a Phase II trial on an experimental rheumatoid arthritis treatment after less-than-stellar interim results were examined.

Read More »

New acne diagnoses linked to increased MDD risk

In the first year after being told by a doctor that they have acne, patients’ risk for a diagnosis of major depressive disorder spikes by more than 60 percent compared to the general population.

Read More »

Data Shows Long-Term Skin Clearance With Tremfya

New data from the VOYAGE 2 club incalculable trial demonstrated high efficacy response rates were achieved with continuous Tremfya (guselkumab) treatment versus withdrawal.

Read More »

Top 10 Pipelines 2018 Annual Report

Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.

Read More »

U.S. FDA looks to pave way for earlier-stage Alzheimer’s drugs

U.S. regulators proposed lowering the bar for clinical trial success for experimental Alzheimer’s drugs.

Read More »

Merck KGaA, Pfizer’s immunotherapy fails in lung cancer trial

Merck KGaA and Pfizer Inc. received a setback for their drug Bavencio, which is a late starter in the cancer immunotherapy field.

Read More »

Merck scraps another late-stage Alzheimer’s drug study

Merck & Co. Inc. ended the late-stage trial of the Alzheimer’s drug verubecestat because it was unlikely to work.

Read More »

Tetraphase’s antibiotic fails late-stage study

Tetraphase Pharmaceuticals Inc.’s lead experimental antibiotic to treat serious infections did not meet the main goals in a late-stage study.

Read More »

Eisai’s Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet

Eisai Co. Ltd. announced that the results of a Phase III study of its in-house discovered and developed anticancer agent lenvatinib mesylate in patients with hepatocellular carcinoma were published in the online version of The Lancet.

Read More »

Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema

Genentech announced encouraging results from the Phase II BOULEVARD study. In people with vision loss from diabetic macular edema, treatment with intravitreal RG7716 resulted in clinically meaningful and statistically significant improvements in visual acuity gains compared with ranibizumab alone.

Read More »

Sanofi Abandons Multiple Mid-Stage Drug Programs

As part of the company’s fourth-quarter 2017 earnings report, Paris-based Sanofi released a pipeline update showing it plans to halt several mid-stage drug programs.

Read More »

Biogen stops testing Tysabri to treat stroke after study fails

Biogen Inc. will stop testing the company’s established drug Tysabri for the treatment of acute ischemic stroke after it failed a mid-stage study.

Read More »

High blood pressure in pregnancy may not disappear afterward

Women who develop high blood pressure during pregnancy may have the condition reappear within a year of delivery, and many of them may go undiagnosed because the problem only surfaces at night, a new study suggests.

Read More »

Xtandi delays prostate cancer spread in early-stage disease

Use of Xtandi in early-stage prostate cancer on top of standard hormone therapy reduced the risk of disease spreading or death by 71 percent compared with hormone therapy alone.

Read More »

Page 2 of 8412345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation